Aethlon Medical (NASDAQ:AEMD – Get Free Report) released its quarterly earnings data on Thursday. The medical equipment provider reported ($4.02) EPS for the quarter, missing the consensus estimate of ($3.92) by ($0.10), FiscalAI reports.
Here are the key takeaways from Aethlon Medical’s conference call:
- Positive Sentiment: Aethlon has entered the final cohort of its Australian oncology trial, with only two additional participants needed if no further safety events occur; the company targets completion of treatments and follow-up by year-end 2026 or early 2027.
- Positive Sentiment: Preliminary, unstatistical analyses from cohort 2 showed more consistent and longer-lasting reductions in extracellular vesicles and cancer-related microRNAs, along with favorable directional changes in lymphocyte subsets and immunotherapy-related laboratory ratios than in cohort 1.
- Neutral Sentiment: Preclinical research found that the Hemopurifier’s resin can bind extracellular vesicles in long COVID samples and reduce certain inflammation- and immune-dysregulation-associated microRNAs; the company is evaluating potential clinical paths and additional work in lupus and heart disease related to chronic kidney disease.
- Positive Sentiment: Cash and cash equivalents totaled approximately $4.9 million at quarter-end, and a subsequent public offering raised about $4 million in gross proceeds; management believes current resources can fund operations for at least 12 months, while quarterly operating expenses declined 11.9% year over year to approximately $1.6 million.
Aethlon Medical Stock Down 3.6%
AEMD traded down $0.11 during trading on Thursday, reaching $2.93. 19,564 shares of the company were exchanged, compared to its average volume of 63,320. The company’s 50-day moving average is $5.12 and its two-hundred day moving average is $8.91. The company has a market cap of $1.90 million, a price-to-earnings ratio of -0.04 and a beta of 1.41. Aethlon Medical has a 12-month low of $2.63 and a 12-month high of $137.00.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on AEMD
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in Aethlon Medical, Inc. (NASDAQ:AEMD – Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical at the end of the most recent quarter. 1.99% of the stock is owned by institutional investors and hedge funds.
Aethlon Medical Company Profile
Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.
The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.
Read More
- Five stocks we like better than Aethlon Medical
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
